SCHEMBL4103534

SCHEMBL4103534

CNC(CC(C)C)C(=O)NCCC1C(Nc2nccc(N3CCCCCC3)n2)CCCN1C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 9/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ CXCR4 P61073 2/20 0.37
▸ ACACB O00763 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CACNA1B Q00975 1/20 0.34
▸ MRGPRX1 Q96LB2 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ NR2C2 P49116 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ TAB1 Q15750 1/20 0.34
▸ MAPK8 P45983 1/20 0.34
▸ ALK Q9UM73 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5579931 1.00 HRH4 (0.38) HRH4KDM4EALDH1A1NPSR1CXCR4
SCHEMBL4122189 0.89 HRH4 (0.39) HRH4KDM4EALDH1A1NPSR1CXCR4
SCHEMBL4110343 0.88 CXCR4 (0.40) HRH4CXCR4ACACBMAPK8ALK
SCHEMBL4105651 0.88 CXCR4 (0.40) HRH4CXCR4ACACBMAPK8ALK
SCHEMBL4116420 0.86 CXCR4 (0.43) HRH4CXCR4MRGPRX1ALK
SCHEMBL4116258 0.85 CXCR4 (0.40) HRH4CXCR4ACACBMRGPRX1MAPK8
SCHEMBL4110044 0.85 CXCR4 (0.40) HRH4CXCR4ACACBMRGPRX1MAPK8
SCHEMBL13696571 0.84 HRH4 (0.40) HRH4CXCR4ALK
SCHEMBL4111574 0.84 CXCR4 (0.39) HRH4CXCR4ACACBMRGPRX1MAPK8
SCHEMBL2006649 0.84 CXCR4 (0.39) HRH4CXCR4ACACBMRGPRX1MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 HRH4 152/4885KDM4E 4423/4885ALDH1A1 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback